<p>截至 2026 年 2 月 2 日，医疗保健行业的三只股票可能正在向那些将动量视为交易决策关键标准的投资者发出真正的警告。</p>
<p>相对强弱指数（RSI）是一种动量指标，它比较股票在价格上涨时的强度与价格下跌时的强度。当与股票的价格走势进行比较时，它可以为交易者提供更好的短期表现预判。根据 Benzinga Pro，当 RSI 超过 70 时，通常被认为是超买。</p>
<p>以下是该行业最新的主要超买股票名单。</p>
<h3><strong>Brookdale Senior Living Inc (NYSE: BKD)</strong></h3>
<ul>
<li>在 1 月 28 日，Brookdale Senior Living 报告了 2025 财年的初步收入为 32 亿美元。Brookdale 首席执行官 Nick Stengle 表示：“我们对 2025 年取得的进展感到满意，并对未来几年在非常有利的行业供需动态下进一步为股东创造价值的机会感到非常兴奋。” 该公司的股票在过去一个月上涨了约 39%，52 周高点为 15.06 美元。</li>
<li><strong>RSI 值：</strong> 89.1</li>
<li><strong>BKD 价格走势：</strong> Brookdale Senior Living 的股票在周五上涨了 3.5%，收于 15.00 美元。</li>
<li>Edge 股票评级：97.10 动量分数。</li>
</ul>
<p></p>
<h3><strong>Mirum Pharmaceuticals Inc (NASDAQ: MIRM)</strong></h3>
<ul>
<li>在 1 月 30 日，摩根士丹利分析师 Michael Ulz 维持 Mirum Pharmaceuticals 的超配评级，并将目标价格从 95 美元上调至 123 美元。该公司的股票在过去一个月上涨了约 31%，并且 52 周高点 为 103.81 美元。</li>
<li><strong>RSI 值：</strong> 80.8</li>
<li><strong>MIRM 价格走势：</strong> Mirum Pharmaceuticals 的股票在周五上涨了 0.3%，收于 103.22 美元。</li>
</ul>
<h3><strong>Amicus Therapeutics, Inc.</strong> (NASDAQ: FOLD)</h3>
<ul>
<li>在 12 月 19 日，Amicus Therapeutics 宣布将被 BioMarin 收购。该公司的股票在过去六个月上涨了约 139%，并且 52 周高点 为 14.38 美元。</li>
<li><strong>RSI 值：</strong> 80.4</li>
<li><strong>FOLD 价格走势：</strong> Amicus Therapeutics 的股票在周五上涨了 0.1%，收于 14.29 美元。</li>
</ul>
<p>了解更多关于 BZ Edge 排名的信息——点击查看该行业其他 股票的评分及其比较。</p>
<p>照片来源于 Shutterstock</p>

MIRM

纽交所高增长板生物技术指数 ETF - First Trust

IBBQ

<p>三只医疗股票因高动量指标显示出潜在下跌的迹象。布鲁克代尔老年关怀公司（Brookdale Senior Living，BKD）的相对强弱指数（RSI）为 89.1，预计 2025 财年的收入为 32 亿美元，股价收于 15.00 美元。Mirum Pharmaceuticals（MIRM）的 RSI 为 80.8，目标价上调至 123 美元，收于 103.22 美元。Amicus Therapeutics（FOLD）的 RSI 为 80.4，正准备被拜玛林制药（BioMarin）收购，收于 14.29 美元。这些股票在最近几个月显著上涨，引发了对其高估值的担忧</p>

<p>As of Feb. 2, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.</p>
<div class="lb-trans"><p>截至 2026 年 2 月 2 日，医疗保健行业的三只股票可能正在向那些将动量视为交易决策关键标准的投资者发出真正的警告。</p>
</div><p>The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.</p>
<div class="lb-trans"><p>相对强弱指数（RSI）是一种动量指标，它比较股票在价格上涨时的强度与价格下跌时的强度。当与股票的价格走势进行比较时，它可以为交易者提供更好的短期表现预判。根据 Benzinga Pro，当 RSI 超过 70 时，通常被认为是超买。</p>
</div><p>Here's the latest list of major overbought players in this sector.</p>
<div class="lb-trans"><p>以下是该行业最新的主要超买股票名单。</p>
</div><h3><strong>Brookdale Senior Living Inc (NYSE: BKD)</strong></h3>
<div class="lb-trans"><h3><strong>Brookdale Senior Living Inc (NYSE: BKD)</strong></h3>
</div><ul>
<li>On Jan. 28, Brookdale Senior Living reported FY25 preliminary revenue of $3.2 billion. “We are pleased with the progress we made in 2025 and are very excited about the opportunity we have over the next several years to further drive value for shareholders in light of the very favorable industry supply and demand dynamics and our focus on operational excellence,” said Nick Stengle, Brookdale’s Chief Executive Officer. The company's stock gained around 39% over the past month and has a 52-week high of $15.06.</li>
<li><strong>RSI Value:</strong> 89.1</li>
<li><strong>BKD Price Action:</strong> Shares of Brookdale Senior Living gained 3.5% to close at $15.00 on Friday.</li>
<li>Edge Stock Ratings: 97.10 Momentum score.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 1 月 28 日，Brookdale Senior Living 报告了 2025 财年的初步收入为 32 亿美元。Brookdale 首席执行官 Nick Stengle 表示：“我们对 2025 年取得的进展感到满意，并对未来几年在非常有利的行业供需动态下进一步为股东创造价值的机会感到非常兴奋。” 该公司的股票在过去一个月上涨了约 39%，52 周高点为 15.06 美元。</li>
<li><strong>RSI 值：</strong> 89.1</li>
<li><strong>BKD 价格走势：</strong> Brookdale Senior Living 的股票在周五上涨了 3.5%，收于 15.00 美元。</li>
<li>Edge 股票评级：97.10 动量分数。</li>
</ul>
</div><p></p>
<div class="lb-trans"><p></p>
</div><h3><strong>Mirum Pharmaceuticals Inc (NASDAQ: MIRM)</strong></h3>
<div class="lb-trans"><h3><strong>Mirum Pharmaceuticals Inc (NASDAQ: MIRM)</strong></h3>
</div><ul>
<li>On Jan. 30, Morgan Stanley analyst Michael Ulz maintained Mirum Pharmaceuticals with an Overweight rating and raised the price target from $95 to $123. The company's stock gained around 31% over the past month and has a 52-week high of $103.81.</li>
<li><strong>RSI Value:</strong> 80.8</li>
<li><strong>MIRM Price Action:</strong> Shares of Mirum Pharmaceuticals rose 0.3% to close at $103.22 on Friday.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 1 月 30 日，摩根士丹利分析师 Michael Ulz 维持 Mirum Pharmaceuticals 的超配评级，并将目标价格从 95 美元上调至 123 美元。该公司的股票在过去一个月上涨了约 31%，并且 52 周高点 为 103.81 美元。</li>
<li><strong>RSI 值：</strong> 80.8</li>
<li><strong>MIRM 价格走势：</strong> Mirum Pharmaceuticals 的股票在周五上涨了 0.3%，收于 103.22 美元。</li>
</ul>
</div><h3><strong>Amicus Therapeutics, Inc.</strong> (NASDAQ: FOLD)</h3>
<div class="lb-trans"><h3><strong>Amicus Therapeutics, Inc.</strong> (NASDAQ: FOLD)</h3>
</div><ul>
<li>On Dec. 19, Amicus Therapeutics announced it will be acquired by BioMarin. The company's stock gained around 139% over the past six months and has a 52-week high of $14.38.</li>
<li><strong>RSI Value:</strong> 80.4</li>
<li><strong>FOLD Price Action:</strong> Shares of Amicus Therapeutics gained 0.1% to close at $14.29 on Friday.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 12 月 19 日，Amicus Therapeutics 宣布将被 BioMarin 收购。该公司的股票在过去六个月上涨了约 139%，并且 52 周高点 为 14.38 美元。</li>
<li><strong>RSI 值：</strong> 80.4</li>
<li><strong>FOLD 价格走势：</strong> Amicus Therapeutics 的股票在周五上涨了 0.1%，收于 14.29 美元。</li>
</ul>
</div><p>Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare.</p>
<div class="lb-trans"><p>了解更多关于 BZ Edge 排名的信息——点击查看该行业其他 股票的评分及其比较。</p>
</div><p>Photo via Shutterstock</p>
<div class="lb-trans"><p>照片来源于 Shutterstock</p>
</div>

第一季度可能崩溃的三大医疗保健股票